It is our pleasure to announce that AMBLor® by AMLo Biosciences has received NICE advice under the MedTech Innovation briefing program (MIB 294). Based on the evidence and economics, the technology shows promise for saving the NHS money in the treatment of patients with Melanoma diagnosed at Stage IA, IB, IIA and IIB.
https://bit.ly/3LOAfOY
Through risk stratification, the NHS is now able to reduce outpatient visits by using AMBLor®. These measures will contribute to two of NHS England's recently announced strategies, namely, personalised follow-up care in hospitals and clinics, as well as a drive to reduce 25% of outpatient visits across the NHS. In addition, with the Personalised stratified follow-up (PSFU) program, which has been implemented specifically for cancer patients, this will support that policy and assist NHS Trusts in conforming to the contracts.
https://bit.ly/3KKrLH5
Health Analytical Solutions has supported AMLo Biosciences throughout this process. This includes the submission of all documents, health economics and positioning their value propositions to the NICE team. If you would like to explore how we can support you on this journey, with our hands-on approach and many other Market Access services, please visit our website.
https://bit.ly/3MPuYqr
In addition, read our White Paper on the current state of Melanoma in the NHS and see the benefits of using AMBLor® in clinical practice.
https://bit.ly/3Fg6R1q
#melanomaawareness #melanoma #skincancer #METATOOL